Effects of Empagliflozin Combined with Ursodeoxycholic Acid on Insulin Resistance,Liver Function and Liver Fibrosis in Patients with Type 2 Diabetes Complicated with Non-Alcoholic Fatty Liver Disease
OBJECTIVE:To probe into the effects of empagliflozin combined with ursodeoxycholic acid on insulin resistance,liver function and liver fibrosis in patients with type 2 diabetes complicated with non-alcoholic fatty liver disease(NAFLD).METHODS:A total of 108 patients with type 2 diabetes complicated with NAFLD admitted into the hospital from Jun.2020 to Dec.2022 were selected to be divided into 54 cases in the control group and 54 cases in the research group via random number table method.The control group was given metformin combined with polyene phosphatidyl choline,while the research group was given empagliflozin combined with ursodeoxycholic acid.The changes of insulin resistance,liver function and inflammatory factor levels were compared between two groups before and after treatment.RESULTS:The glycosylated hemoglobin,fasting insulin,fasting blood glucose,insulin resistance index(HOMA-IR)and 2 h postprandial blood glucose,body mass index and waist-hip ratio of the research group after treatment were significantly lower than those before treatment and the control group after treatment,with statistically significant differences(P<0.05),the differences of the above indicators in the control group were not statistically significant before and after treatment(P>0.05).Aspartate transaminase,alanine aminotransferase,γ-glutamyltranspeptidase,total bilirubin and liver stiffness of the research group after treatment were significantly lower than those before treatment and the control group after treatment,with statistically significant differences(P<0.05).The tumor necrosis factor-α,interleukin-6 and C reactive protein of the research group after treatment were significantly lower than those before treatment and the control group after treatment,with statistically significant differences(P<0.05).CONCLUSIONS:The combination of empagliflozin with ursodeoxycholic acid can significantly reduce the insulin resistance level,alleviate liver injury,improve liver fibrosis and reduce serum inflammatory factors in patients with type 2 diabetes complicated with NAFLD.
Type 2 diabetesNon-alcoholic fatty liver diseaseEmpagliflozinUrsodeoxycholic acidInsulin resistance
万方数据
维普
